GeneAssess
New Brunswick · Founded 2012
About GeneAssess
GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging. The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers. In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.
Company Facts
- Founded: 2012
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $500.0K
- Last round: Series Unknown (Jul 2012)
- Website: geneassessinc.com
- Phone: [email protected]
Social Profiles
Canonical: https://fsome.com/organization/geneassess-8356901 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.